Wealthcare Advisory Partners’s NRX Pharmaceuticals NRXP Stock Holding History

Wealthcare Advisory Partners’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,300	Closed	-$8K	–	620
2022 Q2	$8K	Buy	+1,300	New	+$17.1K	﹤0.01%	559
2022 Q1	–	Sell	-1,300	Closed	-$62K	–	581
2021 Q4	$62K	Buy	+1,300	New	+$93.8K	﹤0.01%	570
2021 Q2	–	Sell	-38	Closed	-$13K	–	1393
2021 Q1	$13K	Buy	+38	New	+$13.8K	﹤0.01%	1368

Other funds holding NRXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wealthcare Advisory Partners's NRXP Position: Q3 2022 in Review

Wealthcare Advisory Partners sold out of NRX Pharmaceuticals (NRXP) in Q3 2022, closing a stake of 1,300 shares — an estimated $8K sold.

Wealthcare Advisory Partners first reported a position in NRXP in Q1 2021 and held it in 3 quarters. The position peaked at $62K in Q4 2021. 30 funds tracked by Wall St. Rank hold NRXP as of Q3 2022.

Wealthcare Advisory Partners reported no remaining NRX Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Wealthcare Advisory Partners sold 1,300 NRX Pharmaceuticals shares in Q3 2022, an estimated $8K.
Wealthcare Advisory Partners first reported a position in NRX Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Wealthcare Advisory Partners's NRX Pharmaceuticals position peaked at $62K in Q4 2021.
30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2022.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2022, filed 14 Nov 2022.